Urszula Masiukiewicz, MD
Senior Director, Global Clinical Research and Development, PfizerAbout
Biography
Dr. Urszula Masiukiewicz is an Assistant Clinical Professor of Medicine at Yale School of Medicine and an attending physician at Yale New-Haven Hospital. She obtained her medical degree from Warsaw Medical School, Warsaw, Poland, and completed postgraduate training at the National Institute of Cardiology in Warsaw, Poland and internal medicine residency at the University of Massachusetts-Memorial Medical Center, Worcester, Massachusetts. In 1996 Dr. Masiukiewicz joined Yale University as a fellow in endocrinology and rose to the rank of Assistant Professor. Dr. Masiukiewicz is a Senior Director in Cardiovascular and Metabolic Division at Pfizer, where she has conducted clinical research since 2004. Dr. Masiukiewicz is a part time clinical faculty member at Yale University and has clinical interests in postmenopausal osteoporosis, disorders of calcium metabolism, metabolic bone disease and thyroid disease.
Appointments
Endocrinology
Clinical InstructorPrimary
Other Departments & Organizations
Education & Training
- Fellow Hartford/NIA Center of Excellence
- Yale University School of Medicine (2000)
- Fellow
- Yale University School of Medicine (1999)
- Chief Medical Resident
- UMass Memorial Medical Center (1996)
- Resident
- Medical Center of Central Massachusetts (1995)
- Externship Residency
- UConn, New Britain General Hospital (1993)
- Resident
- National Institute of Cardiology (1988)
- MD
- Warsaw University (1985)
Research
Research at a Glance
Yale Co-Authors
Publications Timeline
Karl Insogna, MD, FACP
Barbara Gulanski, MD, MPH
James Revkin, MD, FACC, FACP, FCCP
Publications
2025
Cardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Receptor Antagonist: Analyses from the VERTIS CV Trial
Cherney D, Frederich R, Pratley R, Cosentino F, Dagogo-Jack S, Pong A, Gantz I, Cater N, Mancuso J, Masiukiewicz U, Cannon C. Cardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Receptor Antagonist: Analyses from the VERTIS CV Trial. Kidney Diseases 2025, 11: 63-74. PMID: 40028005, PMCID: PMC11870670, DOI: 10.1159/000543162.Peer-Reviewed Original ResearchConceptsRenin-angiotensin-aldosterone system inhibitorsMineralocorticoid receptor antagonistsRenin-angiotensin-aldosterone systemUse of diureticsLoop diureticsVERTIS CVBaseline useCardiorenal outcomesReceptor antagonistTreated with RAAS inhibitorsErtugliflozin 5 mgKidney composite outcomeCox proportional hazards modelsAtherosclerotic CV diseaseTreatment effect modificationModification of treatment effectsProportional hazards modelType 2 diabetesErtugliflozin treatmentPlacebo-controlledRenal outcomesEvent of hospitalizationKidney outcomesSystem inhibitorsRAAS inhibitorsHeart failure outcomes captured by adverse event reporting in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial
Pandey A, Kolkailah A, McGuire D, Frederich R, Cater N, Cosentino F, Pratley R, Dagogo‐Jack S, Cherney D, Wynant W, Gantz I, Mancuso J, Masiukiewicz U, Cannon C. Heart failure outcomes captured by adverse event reporting in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial. European Journal Of Heart Failure 2025 PMID: 39792342, DOI: 10.1002/ejhf.3511.Peer-Reviewed Original ResearchConceptsEffects of ertugliflozinAdverse eventsAtherosclerotic cardiovascular diseaseHF eventsHeart failureType 2 diabetesStandardized Medical Dictionary for Regulatory ActivitiesDoses of ertugliflozinImpact of ertugliflozinCardiovascular diseaseCox proportional hazards modelsHeart failure outcomesMedical Dictionary for Regulatory ActivitiesProportional hazards modelHHF eventsVERTIS CVPeripheral edemaCardiac failureErtugliflozinAndersen-Gill modelHazards modelFailure outcomesPlaceboCV trialsRecurrent events
2024
Efficacy and Safety of Apixaban for Pediatric Patients Requiring Anticoagulation for Treatment of Venous Thromboembolism
Driscoll J, O'Brien S, Newburger J, Mitchell L, Holzhauer S, Ahuja S, Rubio A, Gaitonde P, Robertson A, Polinsky M, Masiukiewicz U, Brandao L. Efficacy and Safety of Apixaban for Pediatric Patients Requiring Anticoagulation for Treatment of Venous Thromboembolism. Blood 2024, 144: 295-295. DOI: 10.1182/blood-2024-198612.Peer-Reviewed Original ResearchConceptsDeep vein thrombosisStandard of careLow-molecular-weight heparinVitamin K antagonistsStandard of care groupPulmonary embolismAdverse eventsApixaban groupApixaban concentrationsBleeding eventsPediatric patientsSafety profileIncidence of treatment-emergent adverse eventsLow risk of VTE recurrenceUnfractionated heparinTreatment-emergent adverse eventsRisk of VTE recurrenceStandard of care therapyAge groupsTreatment of venous thromboembolismVTE-related deathSafety of apixabanRecurrent VTE eventsTreatment of VTEMinor bleeding events
2018
Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)
Cannon CP, McGuire DK, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Charbonnel B, Shih WJ, Gallo S, Masiukiewicz U, Golm G, Cosentino F, Lauring B, Terra SG, Investigators V. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). American Heart Journal 2018, 206: 11-23. PMID: 30290289, DOI: 10.1016/j.ahj.2018.08.016.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsMeSH KeywordsAdultAgedBlood GlucoseBridged Bicyclo Compounds, HeterocyclicCardiovascular DiseasesDiabetes Mellitus, Type 2Dose-Response Relationship, DrugDouble-Blind MethodEuropeFemaleFollow-Up StudiesGlycated HemoglobinHumansIncidenceMaleMiddle AgedProspective StudiesSodium-Glucose Transporter 2 InhibitorsSurvival RateTreatment OutcomeUnited StatesConceptsAtherosclerotic cardiovascular diseaseCardiovascular outcome trialsCV deathHeart failureComposite outcomeOutcome trialsMajor adverse CV eventsStage 3 kidney diseaseType 2 diabetes mellitusEfficacy of ertugliflozinVERTIS-CV trialAdverse CV eventsNonfatal myocardial infarctionDouble-blind placeboPeripheral arterial diseaseCoronary artery diseasePeripheral arterial systemCV eventsERTugliflozin effIcacyNonfatal strokeRenal safetyDiabetes durationBaseline characteristicsRenal deathSerum creatinine
2017
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif JC. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. New England Journal Of Medicine 2017, 376: 1527-1539. PMID: 28304242, DOI: 10.1056/nejmoa1701488.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsMeSH KeywordsAntibodiesAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsCardiovascular DiseasesCholesterol, LDLDouble-Blind MethodFemaleFollow-Up StudiesHumansHypercholesterolemiaInjections, SubcutaneousLipidsMaleMiddle AgedPCSK9 InhibitorsProprotein Convertase 9Risk FactorsTreatment FailureConceptsMajor cardiovascular eventsPrimary end pointHigh-risk patientsLDL cholesterol levelsCardiovascular eventsPlacebo groupCholesterol levelsMajor adverse cardiovascular eventsLow-density lipoprotein cholesterolEnd pointSubtilisin kexin type 9Safety of bococizumabAdverse cardiovascular eventsHigh cardiovascular riskNonfatal myocardial infarctionLow-risk patientsInjection site reactionsHumanized monoclonal antibodyDifferent entry criteriaLonger duration trialsShort-duration trialsCardiovascular efficacyNonfatal strokeUrgent revascularizationCardiovascular death
2013
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI. Oral Apixaban for the Treatment of Acute Venous Thromboembolism. New England Journal Of Medicine 2013, 369: 799-808. PMID: 23808982, DOI: 10.1056/nejmoa1302507.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsAcute venous thromboembolismConventional therapy groupPrimary efficacy outcomeVenous thromboembolismMajor bleedingConventional therapyApixaban groupRelevant nonmajorEfficacy outcomesRecurrent symptomatic venous thromboembolismOral factor Xa inhibitorsFixed-dose regimenPrincipal safety outcomeSymptomatic venous thromboembolismDouble-blind studyFactor Xa inhibitorsOral apixabanAdverse eventsComposite outcomeRelative riskThromboembolismXa inhibitorsApixabanSafety outcomesBleeding
2004
Calcium homeostasis and disorders of calcium metabolism during pregnancy and lactation
Masiukiewicz U, Insogna K. Calcium homeostasis and disorders of calcium metabolism during pregnancy and lactation. In Medical Complications During Pregnancy, 6th edition. Burrow G, Duffy T, editors.Books
2003
Maternal calcium and skeletal homeostasis during pregnancy and lactation
Masiukiewicz U, Insogna K. Maternal calcium and skeletal homeostasis during pregnancy and lactation. In The DeGrooth Textbook of Endocrinology, DeGrooth L, Burrow G, editors. Endotext.org., 2003.Books
2002
Role of the interleukin-6/interleukin-6 soluble receptor cytokine system in mediating increased skeletal sensitivity to parathyroid hormone in perimenopausal women.
Insogna K, Mitnick M, Pascarella J, Nakchbandi I, Grey A, Masiukiewicz U. Role of the interleukin-6/interleukin-6 soluble receptor cytokine system in mediating increased skeletal sensitivity to parathyroid hormone in perimenopausal women. Journal Of Bone And Mineral Research 2002, 17 Suppl 2: n108-16. PMID: 12412787.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsMeSH KeywordsAdultAnimalsBone and BonesBone ResorptionCollagenCollagen Type ICytokinesDisease Models, AnimalEstrogensFemaleFollow-Up StudiesHumansHyperparathyroidismInterleukin-6MenopauseMiceMiddle AgedOsteoporosis, PostmenopausalParathyroid HormonePeptidesPostmenopausePredictive Value of TestsPremenopauseReceptors, Interleukin-6Reference ValuesRetrospective StudiesConceptsIL-6/ILInterleukin-6Skeletal sensitivityPerimenopausal periodPrimary hyperparathyroidismPerimenopausal womenCytokine systemInterleukin-6 soluble receptorSerum IL-6 valuesEstrogen-deficient stateUrine N-telopeptideInterleukin-6/interleukinAction of PTHGroup of patientsIL-6 valuesSerum IL-6/ILEstrogen modulatesIL-6sRIL-6sR.Perimenopausal groupUrine NTXPremenopausal womenSkeletal complicationsCytokine profileExaggerated releaseEvidence that the IL-6/IL-6 Soluble Receptor Cytokine System Plays a Role in the Increased Skeletal Sensitivity to PTH in Estrogen-Deficient Women
Masiukiewicz US, Mitnick M, Gulanski BI, Insogna KL. Evidence that the IL-6/IL-6 Soluble Receptor Cytokine System Plays a Role in the Increased Skeletal Sensitivity to PTH in Estrogen-Deficient Women. The Journal Of Clinical Endocrinology & Metabolism 2002, 87: 2892-2898. PMID: 12050269, DOI: 10.1210/jcem.87.6.8577.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsEstrogen-deficient womenIL-6/ILSkeletal sensitivityIL-6IL-6sREstrogen deficiencyCytokine systemIL-6 soluble receptorUrine N-telopeptideAction of PTHPrevious animal studiesNTx excretionPTH infusionPostmenopausal womenSerum calciumN-telopeptideCytokine productionTNF-alphaExaggerated increaseIL-1betaHormonal statusBaseline valuesSoluble receptorAnimal studiesColony-stimulating factor-1
Academic Achievements & Community Involvement
Activities
activity Temporal Effects of Teriparatide on Bone Microarchitecture Assessed by High Resolution Peripheral Quantitative Computerized Tomography and Paired Bone Biopsies in Postmenopausal Women with Osteoporosis
01/01/2009 - PresentOral PresentationTemporal Effects of Teriparatide on Bone Microarchitecture Assessed by High Resolution Peripheral Quantitative Computerized Tomography and Paired Bone Biopsies in Postmenopausal Women with OsteoporosisDetailsDenver, CO, United StatesSponsored by American Society of Bone and Mineral Researchactivity . Temporal Changes in Bone Strength During 12 Months of Treatment with Teriparatide in Post-Menopausal Women with Osteoporosis
01/01/2009 - PresentOral Presentation. Temporal Changes in Bone Strength During 12 Months of Treatment with Teriparatide in Post-Menopausal Women with OsteoporosisDetailsDenver, CO, United StatesSponsored by American Society for Bone and Mineral Research
Honors
honor Young Investigator Award
07/01/2000National AwardAmerican Society for Bone and Mineral ResearchDetailsUnited Stateshonor Endocrine Fellows Foundation Research Award
07/01/1998National AwardEndocrine Fellows FoundationDetailsUnited Stateshonor Hartford/NIA Center of Excellence in Aging
07/01/1998Regional AwardYale ResearchDetailsUnited Stateshonor Clinical Scientist Award
07/01/1998National AwardNIH NIDDKDetailsUnited States